{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"PFS was defined as the time from registration to progression or death due to any cause.\n\nProgression was defined as any one or more of the following:\n\nAn increase of 25% from lowest confirmed response in:\n\n* Serum M-component (absolute increase \\>= 0.5g/dl)\n* Urine M-component (absolute increase \\>= 200mg/24hour\n* Difference between involved and uninvolved Free Light Chain levels (absolute increase \\>= 10mg/dl)\n* Bone marrow plasma cell percentage (absolute increase of \\>=10%)\n* Definite development of new bone lesion or soft tissue plasmacytomas","dispersionType":"95% Confidence Interval","groups":[{"description":"Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\\^2)","id":"OG000","title":"Anti-thymocyte Globulin/Melphalan"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}